Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade Compared With Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary Intervention
Top Cited Papers
Open Access
- 19 February 2003
- journal article
- clinical trial
- Published by American Medical Association (AMA) in JAMA
- Vol. 289 (7) , 853-863
- https://doi.org/10.1001/jama.289.7.853
Abstract
Unfractionated heparin has been the standard of adjunctive antithrombin therapy during percutaneous coronary intervention (PCI) for more than 25 years. Yet heparin is subject to important intrinsic limitations, including unpredictable pharmacokinetics, inhibition by plasma proteins, and the potential to activate platelets.1-4 Considerable reductions in periprocedural complications have been achieved with administration of glycoprotein IIb/IIIa (Gp IIb/IIIa) antagonists in addition to heparin.5 These potent platelet inhibitors are not used universally, however, in part because of concerns about cost and increased bleeding risk.Keywords
This publication has 34 references indexed in Scilit:
- The REPLACE 1 trial: a pilot study of bivalirudin versus heparin during percutaneous coronary intervention with stenting and GP IIb/IIIa blockadeJournal of the American College of Cardiology, 2002
- Comparison of Two Platelet Glycoprotein IIb/IIIa Inhibitors, Tirofiban and Abciximab, for the Prevention of Ischemic Events with Percutaneous Coronary RevascularizationNew England Journal of Medicine, 2001
- Statistical Methods for Comparison to Placebo in Active-Control TrialsDrug Information Journal, 2001
- Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockadeThe Lancet, 1998
- Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularizationJournal of the American College of Cardiology, 1998
- Platelet Glycoprotein IIb/IIIa Receptor Blockade and Low-Dose Heparin during Percutaneous Coronary RevascularizationNew England Journal of Medicine, 1997
- Trials to assess equivalence: the importance of rigorous methodsBMJ, 1996
- Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary AngioplastyNew England Journal of Medicine, 1994
- Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.Journal of Clinical Investigation, 1990
- Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinaseJournal of the American College of Cardiology, 1988